3 Top Stocks That Could Still Rocket Higher in 2024 [Yahoo! Finance]
BridgeBio Pharma, Inc. (BBIO)
Last bridgebio pharma, inc. earnings: 3/2 08:29 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
Investors looking for stocks that could make dramatic movements in a short, defined time frame want to turn their attention toward the biopharmaceutical industry. There are less than three months left before the end of 2024, but that's plenty of time to see dramatic stock price activity from BridgeBio Pharma (NASDAQ: BBIO) PTC Therapeutics (NASDAQ: PTCT) , and Vertex Pharmaceuticals (NASDAQ: VRTX) The U.S. Food and Drug Administration (FDA) is reviewing applications from all three of these drugmakers, and those reviews are expected to wrap up by the end of the year. A positive decision from the FDA could push these stocks up to new heights, but the agency is more concerned about public health than your stock portfolio's performance. Here's what everyday investors should know about upcoming events that industry experts will watch closely. 1. BridgeBio Pharma At the moment, Pfizer 's Vyndaqel is the only easy-to-swallow treatment approved by the FDA to treat folks with transt
Show less
Read more
Impact Snapshot
Event Time:
BBIO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BBIO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BBIO alerts
High impacting BridgeBio Pharma, Inc. news events
Weekly update
A roundup of the hottest topics
BBIO
News
- BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market [Yahoo! Finance]Yahoo! Finance
- The Consensus EPS Estimates For BridgeBio Pharma, Inc. (NASDAQ:BBIO) Just Fell Dramatically [Yahoo! Finance]Yahoo! Finance
- Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months [Yahoo! Finance]Yahoo! Finance
- Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 MonthsGlobeNewswire
- BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia [Yahoo! Finance]Yahoo! Finance
BBIO
Earnings
- 11/12/24 - Beat
BBIO
Sec Filings
- 11/20/24 - Form 4
- 11/20/24 - Form 4
- 11/19/24 - Form 4
- BBIO's page on the SEC website